US89357L3033 - Common Stock
TRANSCODE THERAPEUTICS INC
NASDAQ:RNAZ (5/3/2024, 7:16:04 PM)
After market: 0.7813 -0.04 (-4.72%)0.82
+0.11 (+15.98%)
Transcode Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2021-04-28. TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Its preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. The company also has two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment, and TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells, as well as TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines that are designed to activate cytotoxic immune responses.
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS
P: 18573016857
CEO: Robert Michael Dudley
Employees: 19
Which stocks are moving after the closing bell on Thursday?
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors...
TransCode Therapeutics Reports 2023 Results; Provides Business Update...
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy
Here you can normally see the latest stock twits on RNAZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: